Related Experiment Video

Updated: Jun 5, 2026

Identification of Kinase-substrate Pairs Using High Throughput Screening
11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks

Laura Gonzalez-Malerva1, Jaehong Park, Lihua Zou

  • 1The Virginia G Piper Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.

Proceedings of the National Academy of Sciences of the United States of America
|January 15, 2011
PubMed

Insights

Tamoxifen resistance in breast cancer is a challenge. This study identified HSPB8 and autophagy as key factors, offering new therapeutic targets for improving tamoxifen effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tamoxifen resistance significantly limits breast cancer treatment efficacy.
  • Understanding the molecular mechanisms of tamoxifen resistance is crucial for developing improved therapies.

Purpose of the Study:

  • To investigate the molecular factors contributing to tamoxifen resistance in breast cancer.
  • To identify novel therapeutic targets for overcoming tamoxifen resistance.

Main Methods:

  • Derived tamoxifen-sensitive and resistant MCF7 cell lines.
  • Performed gene-expression profiling to identify resistance signatures.
  • Conducted high-throughput kinase screening to identify resistance-conferring kinases.
  • Investigated the role of HSPB8 and autophagy in tamoxifen response.

Main Results:

  • A 67-gene signature associated with tamoxifen response and patient survival was identified.
  • 31 kinases, including HSPB8, were found to confer tamoxifen resistance.
  • HSPB8 protected cells from tamoxifen by blocking autophagy; its silencing induced cell death.
  • Tamoxifen induced autophagy in sensitive cells but not resistant ones, suggesting autophagy's role in sensitivity.

Conclusions:

  • HSPB8 is a key mediator of tamoxifen resistance, potentially through autophagy inhibition.
  • Autophagy induction may represent a strategy to sensitize resistant breast cancer cells to tamoxifen.
  • These findings highlight potential new therapeutic avenues for tamoxifen-resistant breast cancer.

More Related Videos

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...